Example: Heart Attack

Search clinical trials for: Beta-lapachone

Total 14 results

NCT00622063

Completed

An Extension Study for Patients Previously Treated With ARQ 501

Conditions: Cancer
NCT01502800

Completed

Clinical Trial of ARQ 761 in Advanced Solid Tumors

Conditions: Solid Tumors
NCT00524524

Completed

An Exploratory Biomarker Study of ARQ 501 in Patients With Advanced Solid Tumors

Conditions: Advanced Solid Tumors
NCT00075933

Completed

ARQ 501 in Subjects With Cancer

Conditions: Cancer
NCT00358930

Completed

A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck

Conditions: Head and Neck Neoplasms; Carcinoma, Squamous Cell
NCT00099190

Completed

ARQ 501 in Combination With Docetaxel in Patients With Cancer

Conditions: Carcinoma
NCT00310518

Completed

Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma

Conditions: Cancer
NCT00102700

Completed

ARQ 501 in Combination With Gemcitabine in Subjects With Pancreatic Cancer

Conditions: Pancreatic Cancer; Adenocarcinoma
NCT01285388

Completed

Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers

Conditions: Metabolic Syndrome; Obesity
NCT02514031

Suspended

ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer

Conditions: Pancreatic Cancer
NCT01444677

Completed

Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers

Conditions: Metabolic Syndrome; Obesity
NCT02338856

Completed

Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Male Volunteers

Conditions: Metabolic Syndrome
NCT02029586

Terminated

Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis

Conditions: Nonalcoholic Fatty Liver Disease
NCT03575078

Withdrawn

ARQ761 + PARP Inhibitor in Refractory Solid Tumors

Conditions: Lymphoma